Abstract Bevacizumab (Avastin™, Genentech) is a humanized monoclonal antibody
targeting vascular endothelial growth factor (VEGF), a critical angiogenic factor involved in …

The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular
supply to nourish a growing tumour, was postulated many decades ago, although the …

Angiogenesis is the process by which new blood vessels are created from pre‐existing
vessels. It is essential for the growth and development of normal cells and tissues during …

Abstract Bevacizumab (Avastin; Genentech/Roche), an antibody against vascular
endothelial growth factor, was approved by the US FDA in February 2004 for the first-line …

Angiogenesis is important in the growth and progression of solid tumours. The main pro-
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …

Bevacizumab (Avastin®) is a recombinant, humanized monoclonal antibody against
vascular endothelial growth factor (VEGF) that is used to inhibit VEGF function in vascular …

Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and
an angiogenic inducer in vivo. The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR …

The importance of vascular endothelial growth factor (VEGF) as a regulator of normal and
tumor blood vessel growth has been increasingly characterized over the past two decades …

Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial
growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer …

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in
metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular …